VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO 2018 | A success story: IDH inhibitors for AML

Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX, Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, describes how IDH inhibitors have significantly acute myeloid leukemia (AML) therapy. Dr Perl discusses how these treatments have increased survival rates in AML patients who have previously been unresponsive to therapy and those who were not candidates for intensive chemotherapy. He stresses the importance of personalized, precision medicines.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter